Yuvraj

Key Takeaways: The multi-vendor model in biopharma CMC creates communication risk, timeline gaps, and regulatory complexity Integrated CDMO partnerships consolidate development and manufacturing under...

The protection of patient health starts with ensuring the safety of pharmaceutical products even before they reach healthcare providers. Every recall caused by defective...

Pharmaceutical companies spend extraordinary amounts optimising what they can see. R&D pipelines. Manufacturing yields. Sales force efficiency. Regulatory submission timelines. These are the numbers...

SGD Pharma has entered into a Franco-American OEM collaboration with Prince Sterilization Services, LLC to validate Ready-to-Use (RTU) Type I glass primary packaging solutions...

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.